VVUS : Analysis & Opinions

  1. Short Interest in Biogen Idec and Vertex Shrinks (BIIB, CELG, ...

    June 26, 2013
    Among biotech and emerging pharmaceutical companies, Celgene (NASDAQ: CELG) and saw the most significant rise in short interest ...
  2. Update on Orexigen's Contrave - Analyst Blog

    January 10, 2013
    Orexigen Therapeutics, Inc. (OREX) recently provided an update on its obesity candidate, Contrave. The company, which had ...
  3. Alexion Pharmaceuticals and Other Nasdaq Stocks Making Big Moves ...

    January 2, 2013
    After this morning's trading, the market is looking good. The Nasdaq is trading up 2.3%; the S&P 500 is up 1.8%; and ...
  4. Healthcare Stocks, Including Pharmacyclics, Making Big Moves ...

    December 17, 2012
    On a good day for the market, the Nasdaq has risen 0.5%, the S&P 500 has increased 0.6% and the Dow has moved up 0.5%. ...
  5. Weight Watchers May Be The Best House On An Awful Street

    November 6, 2012
    Weight Watchers continues to struggle to exploit its huge market opportunity.
  6. Novo Nordisk A/S and More Big Movers in Healthcare on November ...

    November 6, 2012
    The Nasdaq remains relatively unchanged, the S&P 500 has climbed 0.4% and the Dow is trading up 0.6% so far today. The ...
  7. Expedia and More Big Movers on the Nasdaq on September 21, 2 ...

    September 21, 2012
    This morning, the Nasdaq has moved little, the S&P 500 has decreased 0.3% and the Dow has been relatively flat. The recent ...
  8. Valeant Pharmaceuticals Int (USA) and Other Healthcare Stocks ...

    August 15, 2012
    The Nasdaq is trading up 0.2%, the S&P 500 has remained steady and the Dow remains relatively unchanged so far today. ...
  9. Arena Pharmaceuticals – One Huge Step Forward, But Many More ...

    June 28, 2012
    ARNA shareholders got some major validation on June 27, 2012, when the company announced that the FDA had formally approved ...
  10. Control May Be Herbalife's Real Long-Term Problem

    June 4, 2012
    Herbalife's model may not be as precarious as feared, but there are some weaknesses and the stock may only see 10% compound ...
  11. Wall Street Isn't Buying The Medifast Story

    March 5, 2012
    Medifast gets a lot of doubt on the Street.
  12. Herbalife – Stealth Emerging Market Play?

    August 5, 2011
    Herbalife continues to reap amazing growth from emerging markets.
  13. Arena's New Data Doesn't Change Obesity Pill Outlook

    May 30, 2011
    Arena's new data isn't new and doesn't address the company's biggest issues.
  14. Weight Watchers: Is There Still Room To Grow?

    May 11, 2011
    Weight Watchers' improved sales strategy has propelled its strong rebound, but it may already be fully valued.
  15. FDA's Bizarro World - Orexigen Gets Panel Approval!

    December 8, 2010
    In a surprise decision, an FDA panel votes to approve Contrave, Orexigen's new obesity drug.
  16. FDA Locked And Loaded For MELA Sciences

    November 16, 2010
    A harsh FDA review sends MELA down sharply before a pivotal panel meeting.
  17. FDA To Obesity Drugs: Drop Dead

    September 20, 2010
    An FDA panel knocks down yet another would-be obesity drug.
  18. There Is Life After Death, At Least In Biotech

    June 22, 2010
    Clinical failure is not the end of the story for all biotechs. How do some survive while others disappear?
  19. Can Investors Fatten Up On Weight Loss?

    June 22, 2010
    Obesity is described as a multi-billion dollar crisis in North America, but how can investors profit from the solutions? ...
Trading Center